The U.S. Food and Drug Administration (FDA) has approved an innovative pancreatic cancer drug developed by Revolution Medicines. Large-scale clinical trials demonstrated that the medication doubles survival rates for patients with advanced disease, representing significant hope for individuals facing this challenging diagnosis.
The once-daily pill, marketed under the brand name Rasonque (daraxonrasib), was approved for adult patients with metastatic pancreatic cancer who have previously received other treatments or are unable to undergo combination chemotherapy. The drug blocks multiple forms of the RAS protein, which drives tumor cell growth in the majority of pancreatic cancers.
Notably, the medication underwent the FDA’s new expedited review procedure, reducing the standard 10–12 month authorization window to just 1–2 months. Demand for the drug was so high that even prior to official approval, the FDA granted over 2,000 patients access under an expanded access (so-called compassionate use) program. According to the manufacturer, a 30-day supply of the medication in the U.S. costs $39,800, though it may be completely free for patients with appropriate insurance and co-pay assistance programs.
Patients taking Rasonque report significantly milder side effects compared to chemotherapy. The drug markedly reduces fatigue and nausea, allowing individuals to maintain their routine daily lives. According to Brian Wolpin, Director of the Gastrointestinal Cancer Center at Dana-Farber Cancer Institute, this authorization is a “long-awaited and well-deserved step forward” for patients and their families.
Analysts predict that given high demand and strong efficacy, the drug’s annual sales could reach $11.5 billion in the long term. According to estimates by the American Cancer Society, over 67,000 people will be diagnosed with pancreatic cancer this year alone, making the arrival of an effective new alternative of vital importance.
